Here's What Key Metrics Tell Us About Sotera Health (SHC) Q3 Earnings

Core Insights - Sotera Health Company (SHC) reported revenue of $311.31 million for the quarter ended September 2025, reflecting a year-over-year increase of 9.1% [1] - Earnings per share (EPS) for the quarter was $0.26, up from $0.17 in the same quarter last year, indicating a positive trend in profitability [1] - The reported revenue exceeded the Zacks Consensus Estimate of $305.33 million by 1.96%, while the EPS surpassed the consensus estimate of $0.22 by 18.18% [1] Financial Performance Metrics - Sotera Health's Sterigenics segment generated net revenues of $192.85 million, exceeding the average estimate of $190.27 million by two analysts, marking a year-over-year increase of 9.8% [4] - The Nelson Labs segment reported net revenues of $55.66 million, which fell short of the estimated $57.98 million, representing a decline of 5% compared to the previous year [4] - Nordion's net revenues reached $62.81 million, surpassing the average estimate of $57.08 million, with a significant year-over-year increase of 22.4% [4] Stock Performance - Shares of Sotera Health have returned +2.4% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]